If you have been reading about reverse-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
Pregnancy complications: Although the risk of pregnancy with an IUD is very small, if one does occur there is an increased risk of serious problems. These include ectopic pregnancy, infection, miscarriage, and early labor and delivery. As many as half the pregnancies that occur in Mirena users may be ectopic. The incidence rate of ectopic pregnancies is approximately one per 1000 users per year. Immediate removal of the IUD is recommended in the case of pregnancy. No pattern of birth defects was found in the 35 babies for whom birth outcomes were available at the time of FDA approval. Infection: The insertion of the IUD does have a small risk of pelvic inflammatory disease (PID). Concurrent infection with gonorrhea or chlamydia at the time of insertion increases the risk of pelvic inflammatory disease. If PID does occur, it will most likely happen within 21 days of insertion. The device itself does not increase the risk of infection. Ovarian cysts: Enlarged follicles (ovarian cysts) have been diagnosed in about 12% of the subjects using a hormonal IUD in studies that use ultrasound to look for cysts, even if asymptomatic. In studies that only evaluate symptomatic cysts, only 4.5% of women complain of any ovarian cysts over 5 or more years of use, and only 0.3% require IUD removal for ovarian cysts. Thus, any issues with ovarian cysts are not of a clinically relevant nature. Most of these follicles are asymptomatic, although some may be accompanied by pelvic pain or dyspareunia. In most cases the enlarged follicles disappear spontaneously after two to three months.
Recent research suggests that neurocognitive, psychosocial, quality of life, growth, nutrition, and bone pathology are slightly suboptimal even for patients who are treated and maintain their Phe levels in the target range if their diets are not supplemented with other amino acids. Classic PKU affects myelination and white-matter tracts in untreated infants; this may be one major cause of neurological problems associated with phenylketonuria. Differences in white-matter development are observable with magnetic resonance imaging. Abnormalities in the gray matter can also be detected, particularly in the motor and premotor cortex, thalamus, and the hippocampus. PKU may resemble amyloid diseases, such as Alzheimer's disease and Parkinson's disease, due to the formation of toxic amyloid-like assemblies of phenylalanine.
Milos Vratislav Novotny (born 19 April 1942) is an American chemist, currently the Distinguished Professor Emeritus and Director of the Novotny Glycoscience Laboratory and the Institute for Pheromone Research at Indiana University, and also a published author. Milos Novotny received his Bachelor of Science from the University of Brno, Czechoslovakia in 1962. In 1965, Novotny received his Ph.D. at the University of Brno. Novotny also holds honorary doctorates from Uppsala University, Masaryk University and Charles University, and he has been a major figure in analytical separation methods. Novotny was recognized for the development of PAGE Polyacrylamide Gel-filled Capillaries for Capillary Electrophoresis in 1993. In his years of work dedicated to analytical chemistry he has earned a reputation for being especially innovative in the field and has contributed a great deal to several analytical separation methods. Most notably, Milos has worked a great deal with microcolumn separation techniques of liquid chromatography, supercritical fluid chromatography, and capillary electrophoresis. Additionally, he is known for his research in proteomics and glycoanalysis and for identifying the first mammalian pheromones.
Sources: en.wikipedia.org
First, Article 102 of the Treaty on the Functioning of the European Union prohibits "abuse by one or more undertakings of a dominant position". A "dominant position" is presumed to exist with over a 50% market share, and may exist with a 39.7% market share. There may also be dominance through control of data, or by a group of undertakings acting collectively, and a corporate group will be treated as a "single economic unit" for the purpose of calculating market share. The prohibited categories of "abuse" are unlimited, but article 102 explicitly spells out the bans on (a) "unfair purchase or selling prices", (b) "limiting production", (c) "applying dissimilar conditions to equivalent transactions", and (d) imposing unconnected "supplementary obligations" to contracts. In a leading case on (a) unfair prices, United Brands Co v Commission held that, although a banana company had a dominant position in its product and geographic markets (because bananas were not easily substituted with other fruit, and its relevant market share was 40 to 45%), prices 7% higher than rivals were not enough to be an abuse. By contrast prices 25% higher than a company's estimated costs were found to be unfair. Unfair pricing also includes predatory pricing, where a company cuts its own selling prices to bankrupt a competitor: there is a presumption of abuse if a company prices "below average variable costs", namely "those which vary depending on the quantities produced". There is no requirement to show losses might be recouped.
Theca cells are responsible for synthesizing androgens, providing signal transduction between granulosa cells and oocytes during development by the establishment of a vascular system, providing nutrients, and providing structure and support to the follicle as it matures. Theca cells are responsible for the production of androstenedione, which is supplied to the neighboring granulosa cells where it is converted into estrone (a weak estrogen) by the enzyme aromatase, and then further converted into estradiol (a strong estrogen) by the enzyme 17β-HSD1. FSH stimulates granulosa cells to synthesize aromatase and 17β-HSD, which is necessary for this process.
== Causes == NMS is usually caused by antipsychotic drug use, but other dopaminergic blocking drugs can also be a cause. Individuals using butyrophenones (such as haloperidol and droperidol) or phenothiazines (such as promethazine and chlorpromazine) are reported to be at greatest risk. However, various atypical antipsychotics such as clozapine, olanzapine, risperidone, quetiapine, and ziprasidone have also been implicated in cases. NMS may also occur in people taking dopaminergic drugs (such as levodopa) for Parkinson's disease, most often when the drug dosage is abruptly reduced. In addition, other drugs with anti-dopaminergic activity, such as the antiemetic metoclopramide, can induce NMS. Tetracyclics with anti-dopaminergic activity have been linked to NMS in case reports, such as the amoxapines. Additionally, desipramine, dothiepin, phenelzine, tetrabenazine, and reserpine have been known to trigger NMS. Whether lithium can cause NMS is unclear. However, concomitant use of lithium is associated with a higher risk of NMS when a person starts on an antipsychotic drug. At the molecular level, NMS is caused by a sudden, marked reduction in dopamine activity, either from withdrawal of dopaminergic agents or blockade of dopamine receptors.
=== Pharmacokinetics === Butane-1,4-diol is rapidly converted into GHB acid by the enzymes alcohol dehydrogenase and aldehyde dehydrogenase, and differing levels of these enzymes may account for differences in effects and side effects between users. While co-administration of ethanol and GHB already poses serious risks, co-administration of ethanol with 1,4-butanediol will interact considerably and has many other potential risks. This is because the same enzymes that are responsible for metabolizing alcohol also metabolize 1,4-butanediol so there is a strong chance of a dangerous drug interaction. Emergency room patients who overdose on both ethanol and 1,4-butanediol often present with symptoms of alcohol intoxication initially and as the ethanol is metabolized the 1,4-butanediol is then able to better compete for the enzyme and a second period of intoxication ensues as the 1,4-butanediol is converted into GHB.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.